Table 3 Lesion detection by modality
From: Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
Primary tumor | Skeletal lesions seen | Soft tissue lesions or organ involvement | Nodes seen | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Ab dose (mg) | No. of cycles | Total | CT scan or BS | Antibody scan | Total | CT scan | Antibody scan | Total | CT scan | Antibody scan | |
Melanoma | 5 | 2 | 0 | 0 | 0 | 3 | 3 | 3 | 1 | 1 | 0 |
Renal cell | 5 | 4 | 3 | 3 | 3 | 6 | 6 | 4 | 3 | 3 | 2 |
Renal cell | 5 | 4 | 2 | 2 | 2 | 9 | 9 | 4 | 1 | 1 | 0 |
Hepatocellular | 10 | 1 | 0 | 0 | 0 | 6 | 6 | 4 | 0 | 0 | 0 |
Melanoma | 10 | 2 | 4 | 4 | 0 | 12 | 12 | 7 | 3 | 3 | 2 |
Melanoma | 10 | 2 | 1 | 1 | 0 | 5 | 5 | 5 | 3 | 3 | 3 |
Renal cell | 10 | 4 | 0 | 0 | 0 | 8 | 7 | 4 | 2 | 2 | 1 |
Adenoca colon | 20 | 2 | 3 | 3 | 2 | 12 | 12 | 10 | 3 | 3 | 0 |
Melanoma | 20 | 2 | 5 | 5 | 5 | 8 | 8 | 2 | 0 | 0 | 0 |
SCC hypoph | 20 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | 1 |
TCC renal pelvis | 20 | 4 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 1 | 0 |
Adenoca colon | 40 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
TCC renal pelvis | 40 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 2 |
Melanoma | 60 | 2 | 1 | 1 | 1 | 8 | 8 | 3 | 3 | 3 | 3 |
Renal cell | 60 | 1 | 0 | 0 | 0 | 5 | 5 | 4 | 2 | 2 | 2 |
Renal cell | 60 | 4 | 0 | 0 | 0 | 6 | 6 | 3 | 0 | 0 | 0 |
Adenoca gastric | 100 | 4 | 0 | 0 | 0 | 5 | 5 | 5 | 3 | 3 | 0 |
Breast | 100 | 1 | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
SCC tongue | 100 | 2 | 1 | 1 | 1 | 3 | 3 | 3 | 0 | 0 | 0 |
TCC-bladder | 100 | 2 | 0 | 0 | 0 | 6 | 6 | 3 | 5 | 5 | 2 |
27 | 27a | 20 | 109 | 108 | 70 | 34 | 34 | 18 | |||